The U.S. Army recently recognized the meritorious performance of the U.S. Army Medical Materiel Development Activity for its contributions to the global fight against the coronavirus.
USAMMDA received the Army Superior Unit Award (ASUA) along with the rest of the U.S. Army Medical Research and Development Command (USAMRDC) team at Fort Detrick, Maryland, according to USAMRDC commanding general, Brig. Gen. Edward Bailey.
“Congratulations to the [USAMRDC team] on being awarded the Army Superior Unit Award for meritorious performance executing the command’s complex mission while supporting the nation’s response to COVID-19,” wrote Bailey in a June 2024 email to staff announcing the achievement. “USAMRDC’s agility and ability to shift resources to support the COVID-19 pandemic response yielded numerous advancements in medical research, testing, screening, and equipment fielding, and helped the nation be well-postured to combat future pandemics and emerging diseases.”
The coronavirus began to spread internationally in late 2019, necessitating a coordinated worldwide response not seen since the Spanish Flu pandemic in the early 1900s. The U.S. response, coordinated and managed by the U.S. Centers for Disease Control and Prevention and aided by government and private health care systems across the country, transformed the national approach to public health crises.
The ASUA recognizes the command’s forward-leaning posture and flexibility in supporting the whole-of-government approach to combating the pandemic, noting USAMRDC’s successful collaborations with DoD, the National Institutes of Health, other government agencies, industry leaders, and laboratories worldwide, according to the award citation issued by the Honorable Christine E. Wormuth, 25th Secretary of the Army.
USAMMDA, which oversees a robust medical development capability to address biological threats and diseases found across the globe, was a vital component of USAMRDC’s all-hands approach to combating the pandemic between March 1, 2020, and Sept. 30, 2021. USAMMDA’s notable contributions to the COVID-19 response included the following:
While the end of the pandemic was officially declared in May 2023, the ASUA serves as a capstone celebrating the command-wide efforts to manage the first global health crisis of the 21st century. The lessons of adaptability, safety, commitment to duty, strength in the face of adversity, and collaborative efforts are not lost on USAMMDA’s current commander, Col. Andy Nuce. Nuce joined USAMMDA in June 2022, after U.S. national response efforts led to COVID-19 immunizations and the refocusing of Army medical development initiatives. He is grateful to accept the award on behalf of all who contributed to USAMMDA’s efforts during the height of the pandemic.
“This award signifies the USAMMDA team’s continued focus and unwavering commitment to developing and fielding modern treatment solutions in the face of uncertainty,” said Nuce. “While we continue to focus on equipping U.S. Warfighters across the globe, the pandemic was a stark reminder of why our mission is so important. The team saw the effects of an international crisis every day, the team felt the burden of the unknown, the team experienced the strength found in unity and working toward a common purpose.
“The impact USAMMDA had during the pandemic is still visible today,” he added. “We are more prepared for uncertainty, better established as a joint-force enabler across the spectrum of combat casualty care, and uniquely positioned to respond as a vital contributor to the Army’s medical development, acquisition, and fielding missions.”
Nuce, who is leading USAMMDA’s transition to the Defense Health Agency, cites the pandemic response as a primer for organizational change. The lessons of COVID-19 have helped, in part, to prepare the USAMMDA team for continued excellence despite the variables caused by uncertainty. The ASUA is a fitting recognition of the team’s immediate and lasting contributions to U.S. Army and DoD medical readiness.
“While the pandemic consumed the attention of all who work in health care over the past few years, our mission to continue preparing for the next war or pandemic never ended, and we are better suited to this purpose than ever due to the lessons learned during the COVID-19 response,” said Nuce. “I am incredibly humbled and honored to accept this award on USAMMDA’s behalf, but the credit for our achievements belongs to every member of the team who worked tirelessly while upholding the standards our Army represents. Congratulations to all for this well-deserved recognition.”
About USAMMDA
The U.S. Army Medical Materiel Development Activity, part of the U.S. Army Medical Research and Development Command, develops, delivers, and fields critical drugs, vaccines, biologics, devices, and medical support equipment to protect and preserve the lives of Warfighters across the globe. USAMMDA project managers guide the development of medical products for the U.S. Army Medical Department, other U.S. Services, the Joint Staff, the Defense Health Agency, and the U.S. Special Forces community. The process takes promising technology from DoD, industry, and academia to U.S. Forces, from the testing required for U.S. Food and Drug Administration approval or licensing to fielding and sustainment of the finished product.